SPORE IN PROSTATE CANCER

每年有38,000多名美国人死于前列腺癌，几乎是两倍 被手枪杀死的人数。骨转移是毁灭性的，而且 当疾病变成激素时，就没有有效的治疗方法了 耐火材料。前列腺孢子更新是一项多学科的研究 解决方法的途径，以减少发病率、发病率和 前列腺癌死亡率如下。预防：DNA 人谷胱甘肽-S转移酶基因甲基化变化 在这项资助中发现的是最常见的基因组变化 被报道为前列腺癌，而逆转这一点是 拟议的饮食和化学预防研究。遗传学：在 前列腺癌家系的基因连锁研究 将确定候选基因为遗传性前列腺癌 吉恩。肿瘤基因分型和抑癌基因的研究进展 还将进行基因测序。早期发现和 诊断：血清前列腺特异性改变的速度 抗原和血清性类固醇水平将与癌症相关 巴尔的摩老龄化纵向研究的风险，世界上 规模最大、持续时间最长的纵向老化研究。非洲裔美国人 增加了前列腺癌的发病率和死亡率，而这 将在雄激素的分子流行病学中进行研究 受体基因结构。改进的诊断和预后是 通过使用新发现的孢子生物标志物和 高分辨率定量病理学技术的研究 KAI-1肿瘤转移抑制基因的研究 人前列腺癌细胞核中的染色质结构。发病率 减少：加速改善前列腺癌的进展 患者的生活质量，研究的重点是生理学 导致癌症骨转移。处理：该孢子发育 首个针对晚期前列腺癌的人类基因疗法 现在NIH RAC批准进行临床试验。使用新技术的新疗法 基因治疗载体，拓扑异构酶靶向药物， 免疫疗法和放射治疗正在设计中。试点项目 是针对致癌物质和 流行病学因素；以及增强细胞功能的新药物模式 死亡。已经建立了一个大型核心组织库来加速 将人类前列腺研究转化为临床医学。新的 正在培养和建立年轻的调查人员 其他领域的研究人员正被吸引到研究前列腺癌 癌症。这是一项高度互动的临床和基础研究。 致力于将新发现转化为控制 让癌症卧床不起。

Each year prostate cancer kills over 38,000 Americans, almost twice the number killed by handguns. Bone metastasis is devastating, and no effective therapy exists when the disease becomes hormone refractory. This Prostate SPORE renewal is a multidisciplinary approach to address methods to reduce the incidence, morbidity, and mortality of prostate cancer as follows. Prevention: DNA methylation changes in the human glutathione-S-transferase gene discovered in this grant are the most common genomic alterations reported in prostate cancer, and reversing this is a target of the proposed dietary and chemoprevention studies. Genetics: In families with pedigrees of prostate cancer, genetic linkage studies will identify candidate genes as the Hereditary Prostate Cancer gene. Characterization of cancer genotypes and tumor suppressor gene sequencing will also be conducted. Early Detection and Diagnosis: The velocity of change in serum prostatic specific antigen and serum sex-steroid levels will be correlated with cancer risk in the Baltimore Longitudinal Study of Aging, the world's largest and longest longitudinal aging study. African-Americans have increased prostate cancer incidence and mortality, and this will be studied in the molecular epidemiology of the androgen receptor gene structure. Improved diagnosis and prognosis are studied by new algorithms using new SPORE discovered biomarkers and high resolution quantitative pathology techniques; study of the Kai-1 metastasis suppressor gene; and computational study of chromatin structure in human prostate cancer nuclei. Morbidity Reduction: To accelerate progress in improved prostate cancer patient quality of life, research is focused on the physiology of prostrate cancer bone metastases. Treatment: This SPORE developed the first human gene therapy for advanced prostate cancer which is now NIH RAC approved for clinical trials. New therapies using new vectors for gene therapy, topoisomerase-targeted drugs, immunotherapy, and radiotherapy are being designed. Pilot Projects are targeted on population studies of carcinogens and epidemiological factors; and new drug modalities to enhance cell death. A large core tissue bank has been established to accelerate translation of human prostate research to clinical medicine. New young investigators are being developed and established investigators in other fields are being attracted to study prostate cancer. This is a highly interactive clinical and basic research team dedicated to translate new discoveries to the control of prostrate cancer.